A Clinical Investigation to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease

NAActive, not recruitingINTERVENTIONAL

Enrollment

518

Participants

Timeline

Start Date

March 10, 2022

Primary Completion Date

February 28, 2025

Study Completion Date

January 31, 2028

Conditions

Coronary Artery Disease

Interventions

DEVICE

Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS)

Subjects in this arm will be treated with IBS

DEVICE

Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System

Subjects in this arm will be treated with XIENCE

Trial Locations (1)

Fuwai Yunnan Cardiovascular Hospital, Kunming

All Listed Sponsors

lead

Biotyx Medical (Shenzhen) Co., Ltd.

INDUSTRY